FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011677574> ?p ?o ?g. }

• W3011677574 endingPage "332" @default.
• W3011677574 startingPage "327" @default.
• W3011677574 abstract "Objective: To evaluate the efficacy and safety of pirfenidone (PFD) in idiopathic pulmonary fibrosis (IPF) in real-life world. Methods: 47 consecutive patients with IPF taking PFD for at least 12 months (PFD group) were included for analysis, with 47 patients with IPF who did not take PFD as controls. Data were collected from clinical charts to evaluate the lung function parameters and the adverse reactions of PFD. Results: In the PFD group, the percent predicted forced vital capacity (FVC%) and diffusing capacity of carbon monoxide (D(L)CO%) increased by (3.5±7.2)% and (1.1±6.1)% after 6 months of PFD treatment compared with the baseline, while the mean decline of FVC% and D(L)CO% was(2.3±6.7)% and (4.7±6.2)% in the controls (t=2.166, P=0.041; t=2.519, P=0.018). After 12 months of treatment, FVC% increased by (2.3±7.0)% and D(L)CO% decreased by(1.3±12.2)% compared with the baseline, while the mean decline of FVC% and D(L)CO% was (3.3±6.2)% and (5.3±9.8)% in the controls (t=2.292, P=0.030; t=1.047, P=0.303). In the PFD group, 17 patients regularly received pulmonary function test per 6 months. The mean decline in FVC% and D(L)CO% was(6.0±8.2)% and(7.0±13.3)% from 6 month before treatment to baseline when PFD was started, while the FVC% increased by (3.9±7.8)% and D(L)CO% increased by(1.3±6.6)% after 6 months of treatment compared with the baseline (Z=-2.897, P=0.004; Z=-2.151, P=0.031). The proportion of patients with more than 5% or 10% decline in FVC% decreased significantly after 6 months therapy (P=0.010 and 0.018, respectively). Adverse events were commonly seen in 30 patients while taking pirfenidone. The most common adverse events were gastrointestinal symptoms and skin reactions. Conclusions: In real-life world, PFD therapy for 12 months showed good effectiveness on pulmonary functions in patients with mild to severe IPF. Adverse events were common but mild.目的： 观察真实世界中吡非尼酮治疗特发性肺纤维化(IPF)的疗效和安全性。 方法： 采用回顾性病例对照研究的方法连续入选北京朝阳医院接受吡非尼酮治疗的IPF患者47例(吡非尼酮组)，其中男44例，女3例，年龄48～82岁，平均(66±9)岁；同期未接受吡非尼酮治疗的IPF患者47例(对照组)，均为男性，年龄51～83岁，平均(67±8)岁。按照研究流程记录临床数据，观察吡非尼酮的疗效及不良反应，并进行定期随访。 结果： 随访6个月时吡非尼酮组与对照组FVC占预计值%较基线变化值分别为[(3.5±7.2)%和(－2.3±6.7)%，t＝2.166，P＝0.041)；D(L)CO占预计值%较基线变化值分别为[(1.1±6.1)%和(－4.7±6.2)%，t＝2.519，P＝0.018]；随访12个月时FVC占预计值%较基线变化值分别为[(2.3±7.0)%和(－3.3±6.2)%，t＝2.292，P＝0.030]；D(L)CO占预计值%较基线变化值分别为[(－1.3±12.2)%和(－5.3±9.8)%，t＝1.047，P＝ 0.303]。吡非尼酮组中17例IPF患者规律随访，治疗后6个月与治疗前6个月相比，FVC占预计值%较基线变化值分别为[(3.9±7.8)%和(－6.0 ±8.2)%，Z＝－2.897，P＝0.004]；D(L)CO占预计值%的变化值分别为[(1.3±6.6)%和(－7.0±13.3)%，Z＝－2.151，P＝0.031]。分别以6个月内FVC占预计值%较基线下降≥5%或≥10%为界值进行分析，治疗后6个月患者FVC占预计值%较基线下降≥5%或≥10%的例数显著减少，差异有统计学意义(P＝0.010、0.018)。吡非尼酮治疗期间30例(63.8%)出现不良反应，所有患者均未中断治疗。其中14例出现胃肠道不良反应，11例出现皮肤不良反应。 结论： 在真实世界中随访12个月，IPF患者口服吡非尼酮能够一定程度地延缓肺功能下降，对吡非尼酮耐受良好。." @default.
• W3011677574 created "2020-03-23" @default.
• W3011677574 creator A5000850328 @default.
• W3011677574 creator A5014472778 @default.
• W3011677574 creator A5021044404 @default.
• W3011677574 creator A5064822334 @default.
• W3011677574 date "2018-05-12" @default.
• W3011677574 modified "2023-10-14" @default.
• W3011677574 title "[Real-life experience with pirfenidone in idiopathic pulmonary fibrosis]." @default.
• W3011677574 doi "https://doi.org/10.3760/cma.j.issn.1001-0939.2018.05.004" @default.
• W3011677574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29747274" @default.
• W3011677574 hasPublicationYear "2018" @default.
• W3011677574 type Work @default.
• W3011677574 sameAs 3011677574 @default.
• W3011677574 citedByCount "1" @default.
• W3011677574 countsByYear W30116775742022 @default.
• W3011677574 crossrefType "journal-article" @default.
• W3011677574 hasAuthorship W3011677574A5000850328 @default.
• W3011677574 hasAuthorship W3011677574A5014472778 @default.
• W3011677574 hasAuthorship W3011677574A5021044404 @default.
• W3011677574 hasAuthorship W3011677574A5064822334 @default.
• W3011677574 hasConcept C126322002 @default.
• W3011677574 hasConcept C141071460 @default.
• W3011677574 hasConcept C165637977 @default.
• W3011677574 hasConcept C197934379 @default.
• W3011677574 hasConcept C2777714996 @default.
• W3011677574 hasConcept C2778341716 @default.
• W3011677574 hasConcept C2779832356 @default.
• W3011677574 hasConcept C3018587741 @default.
• W3011677574 hasConcept C55520419 @default.
• W3011677574 hasConcept C71924100 @default.
• W3011677574 hasConcept C75603125 @default.
• W3011677574 hasConcept C90924648 @default.
• W3011677574 hasConceptScore W3011677574C126322002 @default.
• W3011677574 hasConceptScore W3011677574C141071460 @default.
• W3011677574 hasConceptScore W3011677574C165637977 @default.
• W3011677574 hasConceptScore W3011677574C197934379 @default.
• W3011677574 hasConceptScore W3011677574C2777714996 @default.
• W3011677574 hasConceptScore W3011677574C2778341716 @default.
• W3011677574 hasConceptScore W3011677574C2779832356 @default.
• W3011677574 hasConceptScore W3011677574C3018587741 @default.
• W3011677574 hasConceptScore W3011677574C55520419 @default.
• W3011677574 hasConceptScore W3011677574C71924100 @default.
• W3011677574 hasConceptScore W3011677574C75603125 @default.
• W3011677574 hasConceptScore W3011677574C90924648 @default.
• W3011677574 hasIssue "5" @default.
• W3011677574 hasLocation W30116775741 @default.
• W3011677574 hasOpenAccess W3011677574 @default.
• W3011677574 hasPrimaryLocation W30116775741 @default.
• W3011677574 hasRelatedWork W1547683341 @default.
• W3011677574 hasRelatedWork W1708007155 @default.
• W3011677574 hasRelatedWork W2063764520 @default.
• W3011677574 hasRelatedWork W2085097145 @default.
• W3011677574 hasRelatedWork W2340104373 @default.
• W3011677574 hasRelatedWork W2555155415 @default.
• W3011677574 hasRelatedWork W2896338416 @default.
• W3011677574 hasRelatedWork W2991333012 @default.
• W3011677574 hasRelatedWork W3092981400 @default.
• W3011677574 hasRelatedWork W3107758297 @default.
• W3011677574 hasVolume "41" @default.
• W3011677574 isParatext "false" @default.
• W3011677574 isRetracted "false" @default.
• W3011677574 magId "3011677574" @default.
• W3011677574 workType "article" @default.